1513.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 13:38):

Stats
आज की मात्रा	846 183
औसत मात्रा	662 061
बाजार मूल्य	35.17B
EPS	HKD0.500 ( 2023-10-24 )
Last Dividend	HKD1.744 ( 2023-07-04 )
Next Dividend	HKD0 ( N/A )
P/E	11.96
ATR14	HKD0.0620 (0.23%)

मात्रा सहसंबंध

लंबा: 0.08 (neutral)

छोटा: 0.14 (neutral)

Signal:(57.6) Neutral

Livzon Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Livzon Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

-0.73
( moderate negative )

-0.30
( neutral )

0.00
( neutral )

-0.85
( strong negative )

0.35
( neutral )

0.83
( strong )

Livzon Pharmaceutical वित्तीय

Annual	2023
राजस्व:	HKD12.43B
सकल लाभ:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2023
राजस्व:	HKD12.43B
सकल लाभ:	HKD7.96B (64.08 %)
EPS:	HKD2.10

FY	2022
राजस्व:	HKD12.63B
सकल लाभ:	HKD8.17B (64.68 %)
EPS:	HKD2.04

FY	2021
राजस्व:	HKD12.06B
सकल लाभ:	HKD7.81B (64.75 %)
EPS:	HKD1.900

Financial Reports:

No articles found.

Livzon Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD1.744 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Livzon Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.98 - good (99.81%) | Divividend Growth Potential Score: 6.52 - Stable (30.36%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.221	2014-07-08
Last Dividend	HKD1.744	2023-07-04
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	HKD9.31	--
Avg. Dividend % Per Year	0.00%	--
Score	3.07	--
Div. Sustainability Score	9.98
Div.Growth Potential Score	6.52
Div. Directional Score	8.25	--

Next Divdend (Est)
(2024-06-24)

HKD1.912 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.07

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
6811.HK	Ex Dividend Knight	2023-10-05	Semi-Annually	0.00%
1908.HK	Ex Dividend Junior	2023-06-01	Sporadic	0.00%
0941.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
0057.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
2899.HK	Ex Dividend Knight	2023-05-30	Annually	0.00%
1508.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
0553.HK	Ex Dividend Junior	2023-07-03	Annually	0.00%
8270.HK	No Dividend Player	2023-06-30	Sporadic	0.00%
2016.HK	Ex Dividend Junior	2023-05-17	Annually	0.00%
1084.HK	Ex Dividend Junior	2023-06-06	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.161	1.500	6.77	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0786	1.200	7.38	8.86	[0 - 0.3]
returnOnEquityTTM	0.142	1.500	9.53	10.00	[0.1 - 1]
payoutRatioTTM	0.799	-1.000	2.01	-2.01	[0 - 1]
currentRatioTTM	2.06	0.800	4.69	3.75	[1 - 3]
quickRatioTTM	1.802	0.800	4.11	3.29	[0.8 - 2.5]
cashRatioTTM	1.338	1.500	3.68	5.52	[0.2 - 2]
debtRatioTTM	0.141	-1.500	7.64	-10.00	[0 - 0.6]
interestCoverageTTM	24.70	1.000	1.962	1.962	[3 - 30]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	3.25	2.00	8.37	10.00	[0 - 20]
debtEquityRatioTTM	0.244	-1.500	9.02	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.645	1.000	2.58	2.58	[0.2 - 0.8]
operatingProfitMarginTTM	0.206	1.000	7.88	7.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.087	1.000	5.07	5.07	[0.2 - 2]
assetTurnoverTTM	0.487	0.800	-0.0887	-0.0709	[0.5 - 2]
Total Score				9.98

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.05	1.000	8.88	0	[1 - 100]
returnOnEquityTTM	0.142	2.50	9.70	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	3.25	2.00	8.92	10.00	[0 - 30]
dividendYielPercentageTTM	6.84	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.14	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0.799	1.500	2.01	-2.01	[0 - 1]
pegRatioTTM	1.132	1.500	5.79	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.316	1.000	4.60	0	[0.1 - 0.5]
Total Score				6.52

Livzon Pharmaceutical

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.